European Urology, ISSN 0302-2838, 2016, Volume 71, Issue 2, pp. e45 - e46
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 10/2011, Volume 53, Issue 8, pp. 780 - 786
Background. The Centers for Disease Control and Prevention (CDC) estimates that 4.1 million Americans have been infected with hepatitis C virus (HCV) and...
HIV | Surveillance | Specimens | Antibodies | AIDS serodiagnosis | AIDS | Infections | Preventive medicine | ARTICLES AND COMMENTARIES | Hepacivirus | Blood | UNITED-STATES | TRIAL | RATES | INFECTIOUS DISEASES | INJECTION-DRUG USERS | MICROBIOLOGY | INFECTION | PREVALENCE | IMMUNOLOGY | OUTREACH | OF-CARE | United States - epidemiology | Hepacivirus - immunology | Humans | Middle Aged | Hepatitis C, Chronic - virology | Male | HIV - immunology | Clinical Laboratory Techniques - standards | Mass Screening - methods | Young Adult | HIV Infections - immunology | Hepatitis C - immunology | Hepatitis C Antibodies - blood | HIV Infections - diagnosis | Sensitivity and Specificity | Adult | Female | Substance Abuse, Intravenous - complications | HIV Infections - virology | Hepatitis C, Chronic - diagnosis | Saliva - virology | Clinical Laboratory Techniques - methods | Hepatitis C - diagnosis | Adolescent | Hepatitis C - virology | Hepatitis C, Chronic - immunology | Aged | Population Surveillance | Control | Anti-antibodies | Causes of | Dosage and administration | HIV (Viruses) | Drug therapy | Hepatitis C | Hepatitis C virus | Health aspects | HIV infection
HIV | Surveillance | Specimens | Antibodies | AIDS serodiagnosis | AIDS | Infections | Preventive medicine | ARTICLES AND COMMENTARIES | Hepacivirus | Blood | UNITED-STATES | TRIAL | RATES | INFECTIOUS DISEASES | INJECTION-DRUG USERS | MICROBIOLOGY | INFECTION | PREVALENCE | IMMUNOLOGY | OUTREACH | OF-CARE | United States - epidemiology | Hepacivirus - immunology | Humans | Middle Aged | Hepatitis C, Chronic - virology | Male | HIV - immunology | Clinical Laboratory Techniques - standards | Mass Screening - methods | Young Adult | HIV Infections - immunology | Hepatitis C - immunology | Hepatitis C Antibodies - blood | HIV Infections - diagnosis | Sensitivity and Specificity | Adult | Female | Substance Abuse, Intravenous - complications | HIV Infections - virology | Hepatitis C, Chronic - diagnosis | Saliva - virology | Clinical Laboratory Techniques - methods | Hepatitis C - diagnosis | Adolescent | Hepatitis C - virology | Hepatitis C, Chronic - immunology | Aged | Population Surveillance | Control | Anti-antibodies | Causes of | Dosage and administration | HIV (Viruses) | Drug therapy | Hepatitis C | Hepatitis C virus | Health aspects | HIV infection
Journal Article
Book
The Journal of Infectious Diseases, ISSN 0022-1899, 9/2011, Volume 204, Issue 6, pp. 825 - 831
Background. The Centers for Disease Control and Prevention (CDC) estimates that 3.2 million Americans are living with chronic hepatitis C virus (HCV) infection...
Hepatitis | Injections | HIV | Screening tests | False negative errors | Specimens | Antibodies | Viruses | Infections | Preventive medicine | UNITED-STATES | INFECTIOUS DISEASES | PLUS RIBAVIRIN | RANDOMIZED-TRIAL | MICROBIOLOGY | PREVALENCE | SETTINGS | IMMUNOLOGY | OUTREACH | DRUG-USERS | THERAPY | INFECTION | OF-CARE | Young Adult | Clinical Laboratory Techniques - methods | Hepatitis C Antibodies - blood | Humans | Sensitivity and Specificity | Adolescent | Immunoassay - methods | Adult | Hepatitis C, Chronic - diagnosis | Mass Screening - methods | Drugs | Evaluation | Care and treatment | Usage | Product/Service Evaluations | Viral antibodies | Diagnosis | Hepatitis C | Drug therapy | Hepatitis C virus | Health aspects | Immune system | Testing
Hepatitis | Injections | HIV | Screening tests | False negative errors | Specimens | Antibodies | Viruses | Infections | Preventive medicine | UNITED-STATES | INFECTIOUS DISEASES | PLUS RIBAVIRIN | RANDOMIZED-TRIAL | MICROBIOLOGY | PREVALENCE | SETTINGS | IMMUNOLOGY | OUTREACH | DRUG-USERS | THERAPY | INFECTION | OF-CARE | Young Adult | Clinical Laboratory Techniques - methods | Hepatitis C Antibodies - blood | Humans | Sensitivity and Specificity | Adolescent | Immunoassay - methods | Adult | Hepatitis C, Chronic - diagnosis | Mass Screening - methods | Drugs | Evaluation | Care and treatment | Usage | Product/Service Evaluations | Viral antibodies | Diagnosis | Hepatitis C | Drug therapy | Hepatitis C virus | Health aspects | Immune system | Testing
Journal Article
Morbidity and Mortality Weekly Report: Recommendations and Reports, ISSN 1057-5987, 8/2012, Volume 61, Issue 4, pp. 1 - 32
Hepatitis C virus (HCV) is an increasing cause of morbidity and mortality in the United States. Many of the 2.7–3.9 million persons living with HCV infection...
Recommendations | Mortality | Conflicts of interest | Information relevance | Hepatocellular carcinoma | Infections | Educational relevance | Hepatitis C | Hepacivirus | Alcohols | Hepacivirus - isolation & purification | United States - epidemiology | Prevalence | Outcome Assessment (Health Care) | Humans | Middle Aged | Risk Factors | Hepatitis C, Chronic - prevention & control | Mass Screening - standards | Male | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - mortality | Counseling | Female | Aged
Recommendations | Mortality | Conflicts of interest | Information relevance | Hepatocellular carcinoma | Infections | Educational relevance | Hepatitis C | Hepacivirus | Alcohols | Hepacivirus - isolation & purification | United States - epidemiology | Prevalence | Outcome Assessment (Health Care) | Humans | Middle Aged | Risk Factors | Hepatitis C, Chronic - prevention & control | Mass Screening - standards | Male | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - mortality | Counseling | Female | Aged
Journal Article
European Urology, ISSN 0302-2838, 11/2019, Volume 76, Issue 5, pp. e139 - e140
Journal Article
Journal of Clinical Virology, ISSN 1386-6532, 2012, Volume 54, Issue 3, pp. 213 - 217
Abstract Background Approximately 4.1 million Americans are estimated to have been infected with hepatitis C virus (HCV), 45–85% of whom are unaware of their...
Infectious Disease | Allergy and Immunology | Screening | Rapid assays | Sensitivity | Specificity | Hepatitis C | UNITED-STATES | PREVALENCE | OUTREACH | TRIAL | RATES | VIROLOGY | HIV | SURVEILLANCE | INFECTION | USERS | OF-CARE | Hepacivirus - immunology | United States | Humans | Male | Virology - methods | Young Adult | Clinical Laboratory Techniques - methods | Hepatitis C - diagnosis | Point-of-Care Systems | Time Factors | Hepatitis C Antibodies - blood | Sensitivity and Specificity | Adolescent | Immunoassay - methods | Adult | Female | Substance Abuse, Intravenous - complications | Virus diseases | Viral antibodies | Drugs | Biological products | Antibodies | Youth | Teenagers | Diagnosis | Hepatitis C virus | Health aspects
Infectious Disease | Allergy and Immunology | Screening | Rapid assays | Sensitivity | Specificity | Hepatitis C | UNITED-STATES | PREVALENCE | OUTREACH | TRIAL | RATES | VIROLOGY | HIV | SURVEILLANCE | INFECTION | USERS | OF-CARE | Hepacivirus - immunology | United States | Humans | Male | Virology - methods | Young Adult | Clinical Laboratory Techniques - methods | Hepatitis C - diagnosis | Point-of-Care Systems | Time Factors | Hepatitis C Antibodies - blood | Sensitivity and Specificity | Adolescent | Immunoassay - methods | Adult | Female | Substance Abuse, Intravenous - complications | Virus diseases | Viral antibodies | Drugs | Biological products | Antibodies | Youth | Teenagers | Diagnosis | Hepatitis C virus | Health aspects
Journal Article
Oncotarget, ISSN 1949-2553, 2015, Volume 6, Issue 26, pp. 22310 - 22327
Freshly isolated human primary NK cells induce preferential lysis of Oral Squamous Carcinoma Stem Cells (OSCSCs) when compared to differentiated Oral Squamous...
Cystatin F | Cathepsins C | NK cells | Anergy | Cathepsin H | LYTIC GRANULES | cathepsins C | DENDRITIC CELLS | cystatin F | IFN-GAMMA | DIPEPTIDYL PEPTIDASE-I | HUMAN NK CELLS | FACTOR-KAPPA-B | anergy | CELL BIOLOGY | CANCER-PATIENTS | cathepsin H | GENE-EXPRESSION | LYSOSOMAL CYSTEINE PROTEASES | GRANZYME-B | Cystatins - immunology | Cell Differentiation - immunology | Killer Cells, Natural - cytology | Humans | Cathepsin C - immunology | Cathepsin H - immunology | Cell Line, Tumor | Clonal Anergy | Killer Cells, Natural - immunology | Biomarkers, Tumor - immunology
Cystatin F | Cathepsins C | NK cells | Anergy | Cathepsin H | LYTIC GRANULES | cathepsins C | DENDRITIC CELLS | cystatin F | IFN-GAMMA | DIPEPTIDYL PEPTIDASE-I | HUMAN NK CELLS | FACTOR-KAPPA-B | anergy | CELL BIOLOGY | CANCER-PATIENTS | cathepsin H | GENE-EXPRESSION | LYSOSOMAL CYSTEINE PROTEASES | GRANZYME-B | Cystatins - immunology | Cell Differentiation - immunology | Killer Cells, Natural - cytology | Humans | Cathepsin C - immunology | Cathepsin H - immunology | Cell Line, Tumor | Clonal Anergy | Killer Cells, Natural - immunology | Biomarkers, Tumor - immunology
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 12/2013, Volume 208, Issue 12, pp. 1934 - 1942
Background. Persons who inject drugs (PWID) are at high risk for acquiring hepatitis C virus (HCV) infection. The Centers for Disease Control and Prevention...
VIRUSES | Sharing injection equipment | Injection drug use | Serosorting | Hepatitis C virus | UNITED-STATES | POPULATION | INFECTIOUS DISEASES | VIRUS-INFECTION | MICROBIOLOGY | PREVALENCE | IMMUNOLOGY | RISK BEHAVIOR | serosorting | sharing injection equipment | HIV-INFECTION | MEN | hepatitis C virus | SURVEILLANCE | USERS | injection drug use | Multivariate Analysis | United States - epidemiology | Drug Users - statistics & numerical data | Humans | Middle Aged | Substance Abuse, Intravenous - epidemiology | Logistic Models | Male | Health Knowledge, Attitudes, Practice | Needle Sharing - statistics & numerical data | Hepatitis C - epidemiology | Risk-Taking | Hepatitis C - virology | Substance Abuse, Intravenous - virology | Adult | Female | Odds Ratio | Prevention | Injections | Usage | Research | Hepatitis C | Risk factors
VIRUSES | Sharing injection equipment | Injection drug use | Serosorting | Hepatitis C virus | UNITED-STATES | POPULATION | INFECTIOUS DISEASES | VIRUS-INFECTION | MICROBIOLOGY | PREVALENCE | IMMUNOLOGY | RISK BEHAVIOR | serosorting | sharing injection equipment | HIV-INFECTION | MEN | hepatitis C virus | SURVEILLANCE | USERS | injection drug use | Multivariate Analysis | United States - epidemiology | Drug Users - statistics & numerical data | Humans | Middle Aged | Substance Abuse, Intravenous - epidemiology | Logistic Models | Male | Health Knowledge, Attitudes, Practice | Needle Sharing - statistics & numerical data | Hepatitis C - epidemiology | Risk-Taking | Hepatitis C - virology | Substance Abuse, Intravenous - virology | Adult | Female | Odds Ratio | Prevention | Injections | Usage | Research | Hepatitis C | Risk factors
Journal Article
Nature Genetics, ISSN 1061-4036, 01/2017, Volume 49, Issue 1, pp. 36 - 45
textabstractDespite the clinical significance of balanced chromosomal abnormalities (BCAs), their characterization has largely been restricted to cytogenetic...
INTELLECTUAL DISABILITY | CHROMOSOME REARRANGEMENTS | DE-NOVO MUTATIONS | SEVERE MENTAL-RETARDATION | GENETICS & HEREDITY | MICRODELETION SYNDROME | DEVELOPMENTAL DELAY | OF-FUNCTION MUTATIONS | SPECTRUM | EPILEPSY | STRUCTURAL VARIATION | Genetic Predisposition to Disease | Genome-Wide Association Study | Congenital Abnormalities - genetics | Gene Rearrangement | Genetic Markers - genetics | Humans | Chromosome Aberrations | Female | Male | Cytogenetics | Nucleotide sequencing | Analysis | Genomics | DNA sequencing | Studies | Medical research | Genetic counseling | Congenital diseases | Intellectual disabilities | Genomes | Mutation | Grants | Localization | structural variation | MEF2C | translocation | inversion | Hi-C | chromothripsis | topologically associated domain (TAD) | congenital anomaly | intellectual disability | autism | balanced chromosomal abnormality
INTELLECTUAL DISABILITY | CHROMOSOME REARRANGEMENTS | DE-NOVO MUTATIONS | SEVERE MENTAL-RETARDATION | GENETICS & HEREDITY | MICRODELETION SYNDROME | DEVELOPMENTAL DELAY | OF-FUNCTION MUTATIONS | SPECTRUM | EPILEPSY | STRUCTURAL VARIATION | Genetic Predisposition to Disease | Genome-Wide Association Study | Congenital Abnormalities - genetics | Gene Rearrangement | Genetic Markers - genetics | Humans | Chromosome Aberrations | Female | Male | Cytogenetics | Nucleotide sequencing | Analysis | Genomics | DNA sequencing | Studies | Medical research | Genetic counseling | Congenital diseases | Intellectual disabilities | Genomes | Mutation | Grants | Localization | structural variation | MEF2C | translocation | inversion | Hi-C | chromothripsis | topologically associated domain (TAD) | congenital anomaly | intellectual disability | autism | balanced chromosomal abnormality
Journal Article
1975, The Heritage of librarianship series, ISBN 0872871134, Volume no. 1, x, 166
Book
European Journal of Clinical Pharmacology, ISSN 0031-6970, 2/2019, Volume 75, Issue 2, pp. 207 - 216
To characterize the pharmacokinetics of ombitasvir, paritaprevir, ritonavir, dasabuvir, and ribavirin in hepatitis C virus (HCV)-infected patients with chronic...
End-stage renal disease | Biomedicine | Chronic kidney disease | Renal impairment | Pharmacology/Toxicology | Hepatitis C virus | Ombitasvir/paritaprevir/ritonavir | Dasabuvir | SURVIVAL | INCREASES | RISK | paritaprevir | DISPOSITION | Ombitasvir | METABOLISM | ritonavir | C VIRUS-INFECTION | PHARMACOLOGY & PHARMACY | INHIBITOR | HEPATITIS-C | ASSOCIATION | DRUG-INTERACTION PROFILE | Kidneys | Renal function | Medicare | Hemodialysis | Ritonavir | Clinical trials | Chronic infection | Viruses | Data processing | Pharmacology | Exposure | Patients | Steady state | Ribavirin | Hepatitis | Dialysis | Kidney diseases | Hepatitis C | Pharmacokinetics
End-stage renal disease | Biomedicine | Chronic kidney disease | Renal impairment | Pharmacology/Toxicology | Hepatitis C virus | Ombitasvir/paritaprevir/ritonavir | Dasabuvir | SURVIVAL | INCREASES | RISK | paritaprevir | DISPOSITION | Ombitasvir | METABOLISM | ritonavir | C VIRUS-INFECTION | PHARMACOLOGY & PHARMACY | INHIBITOR | HEPATITIS-C | ASSOCIATION | DRUG-INTERACTION PROFILE | Kidneys | Renal function | Medicare | Hemodialysis | Ritonavir | Clinical trials | Chronic infection | Viruses | Data processing | Pharmacology | Exposure | Patients | Steady state | Ribavirin | Hepatitis | Dialysis | Kidney diseases | Hepatitis C | Pharmacokinetics
Journal Article
Health Promotion Practice, ISSN 1524-8399, 3/2015, Volume 16, Issue 2, pp. 256 - 263
Background. In 1998, the Centers for Disease Control and Prevention (CDC) published Recommendations for Prevention and Control of Hepatitis C Virus (HCV)...
guidelines | screening | hepatitis | delivery of health care | Hepatitis C - diagnosis | United States - epidemiology | Guideline Adherence | Centers for Disease Control and Prevention (U.S.) - standards | Humans | Risk Factors | Primary Health Care - organization & administration | Mass Screening - organization & administration | Hepatitis C, Chronic - diagnosis | Practice Guidelines as Topic
guidelines | screening | hepatitis | delivery of health care | Hepatitis C - diagnosis | United States - epidemiology | Guideline Adherence | Centers for Disease Control and Prevention (U.S.) - standards | Humans | Risk Factors | Primary Health Care - organization & administration | Mass Screening - organization & administration | Hepatitis C, Chronic - diagnosis | Practice Guidelines as Topic
Journal Article
Polar Biology, ISSN 0722-4060, 4/2011, Volume 34, Issue 4, pp. 521 - 532
The benthos of the southeastern Chukchi Sea shelf is typified by high faunal abundance and biomass resulting from settlement of a large proportion of seasonal...
Marine food web | Microbiology | POC | Zoology | Ecology | Oceanography | Life Sciences | Chukchi Sea | Stable isotopes | Kotzebue Sound | Benthos | Arctic | Plant Sciences
Marine food web | Microbiology | POC | Zoology | Ecology | Oceanography | Life Sciences | Chukchi Sea | Stable isotopes | Kotzebue Sound | Benthos | Arctic | Plant Sciences
Journal Article
Antiviral Therapy, ISSN 1359-6535, 2012, Volume 17, Issue 7, pp. 1409 - 1413
Approximately 4.1 million Americans have been infected with HCV and 45-85% of chronically infected persons are unaware of their status. Rapid anti-HCV assays...
UNITED-STATES | CORE | INFECTIOUS DISEASES | COINFECTION | RISK | PREVALENCE | CARE | INJECTION-DRUG USERS | VIROLOGY | HIV | C VIRUS-INFECTION | PHARMACOLOGY & PHARMACY | HEPATITIS-C | Hepacivirus - isolation & purification | Hepatitis C - diagnosis | United States - epidemiology | Time Factors | Hepacivirus - immunology | Hepatitis C Antibodies - blood | Hepatitis C - epidemiology | Humans | Reagent Kits, Diagnostic | Sensitivity and Specificity | Hepatitis C - virology | Hepatitis C Antigens - immunology
UNITED-STATES | CORE | INFECTIOUS DISEASES | COINFECTION | RISK | PREVALENCE | CARE | INJECTION-DRUG USERS | VIROLOGY | HIV | C VIRUS-INFECTION | PHARMACOLOGY & PHARMACY | HEPATITIS-C | Hepacivirus - isolation & purification | Hepatitis C - diagnosis | United States - epidemiology | Time Factors | Hepacivirus - immunology | Hepatitis C Antibodies - blood | Hepatitis C - epidemiology | Humans | Reagent Kits, Diagnostic | Sensitivity and Specificity | Hepatitis C - virology | Hepatitis C Antigens - immunology
Journal Article